Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q5ST30

UPID:
SYVM_HUMAN

ALTERNATIVE NAMES:
Valyl-tRNA synthetase; Valyl-tRNA synthetase-like

ALTERNATIVE UPACC:
Q5ST30; A2ABL7; B4DET4; B4E3P5; F5GXJ0; F5H323; Q2M2A0; Q59FI1; Q5SQ96; Q5SS98; Q6DKJ5; Q6ZV24; Q96GN2; Q96H77; Q96Q02; Q9H6R2; Q9UFH7

BACKGROUND:
The mitochondrial Valine--tRNA ligase, with alternative names Valyl-tRNA synthetase and Valyl-tRNA synthetase-like, is pivotal in the translation process, ensuring the proper function of the mitochondrial respiratory chain.

THERAPEUTIC SIGNIFICANCE:
Given its association with Combined oxidative phosphorylation deficiency 20, which manifests through diverse clinical features including epilepsy and abnormal liver function, exploring Valine--tRNA ligase could lead to groundbreaking treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.